Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

NCT02062502 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

611

Enrollment

INDUSTRY

Sponsor class

Conditions

Varicella

Interventions

BIOLOGICAL: VARIVAX™ New Seed Process
BIOLOGICAL: VARIVAX™ 2007 process
BIOLOGICAL: M-M-R II™

Sponsor

Merck Sharp & Dohme LLC